People Who Use Fuzeon May Be at 34 Percent Higher Risk for Pneumonia

May 2, 2011

The FDA announced April 28 that people living with HIV who take the entry inhibitor called Fuzeon (enfuvirtide) may be at higher risk for pneumonia. This news comes from a recently completed study that followed 740 people who took Fuzeon compared to 1,110 who didn't.


When Fuzeon was originally approved, data from the 301 and 302 studies showed that more people on Fuzeon suffered from bacterial and other forms of pneumonia almost 12 times as often as those who didn't take it (6.9% vs. 0.6%). More than half were admitted to the hospital, and three others had died.

However, the people in those studies were also in generally poorer health, which may have skewed the original risk for pneumonia. The FDA subsequently required the manufacturer to do follow-up study. The data from that study shows a 34% higher rate of pneumonia in those who took Fuzeon, although it's not clear that the drug is solely responsible for this higher risk.

The prescribing information has now been changed and suggests that people who take Fuzeon should be closely checked for pneumonia symptoms, especially if they have other conditions that may make pneumonia more likely, such as low CD4s, high baseline viral load, smoking, lung disease or injection drug use.

Research Study

Roche. Observational cohort study on the incidence of pneumonia in HIV-1 patients treated with Fuzeon.

This article was provided by Project Inform. Visit Project Inform's website to find out more about their activities, publications and services.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.